Rovadicitinib
Phase 3Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Rovadicitinib is one of 24 small molecule programs targeting Chronic Graft Versus Host Disease. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
25 competitors in Chronic Graft Versus Host Disease
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Rezurock
KKadmon, a Sanofi Company
Approved
Erivedge
RocheApproved
Neoral
NovartisApproved
Olumiant
Eli LillyApproved
Decadron
AAspen Global Incorporated
Approved
Pulmicort
SSalix
Approved
Kyprolis
VVirionyx Corporation Limited
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Qvar
SSchering-Plough
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rovadicitinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details